Stifel Nicolaus initiated coverage on shares of X4 Pharmaceuticals (NASDAQ:XFOR) in a research report report published on Friday, June 7th, Stock Target Advisor reports. The brokerage issued a buy rating and a $27.00 price objective on the stock.
Other research analysts have also recently issued research reports about the company. Canaccord Genuity initiated coverage on X4 Pharmaceuticals in a research report on Tuesday, May 21st. They issued a buy rating and a $27.00 price target on the stock. Cowen initiated coverage on X4 Pharmaceuticals in a research report on Wednesday, June 5th. They issued an outperform rating on the stock.
Shares of NASDAQ:XFOR traded up $0.75 during midday trading on Friday, hitting $15.75. The stock had a trading volume of 44,118 shares, compared to its average volume of 43,658. X4 Pharmaceuticals has a 12 month low of $6.90 and a 12 month high of $29.46. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.59 and a quick ratio of 1.59.
An institutional investor recently bought a new position in X4 Pharmaceuticals stock. Polaris Venture Management Co. V L.L.C. acquired a new position in shares of X4 Pharmaceuticals Inc (NASDAQ:XFOR) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 311,492 shares of the company’s stock, valued at approximately $5,423,000. X4 Pharmaceuticals makes up 4.6% of Polaris Venture Management Co. V L.L.C.’s portfolio, making the stock its 6th largest holding. Polaris Venture Management Co. V L.L.C. owned about 2.51% of X4 Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 14.40% of the company’s stock.
X4 Pharmaceuticals Company Profile
X4 Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Recommended Story: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.